[Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
OBJECTIVE
To determine the clinical toxicities and antitumor effects of a chemotherapy regimen of FTQ, a compound preparation of tegafur, the drug prototype of 5-furacil (5-FU), gimeracil (CDHP), a decomposition inhibitor of 5-FU, oteracil potassium, phosphorylation inhibitor of 5-FU, and combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer.


METHODS
119 patients with inoperable locally or metastatic advanced gastric cancer admitted in 10 hospitals in China were divided into 2 groups: FTQ group (n = 59), undergoing a 3-week regime, i.e. oral use of 80 mg x m(-2) x d(-1) for 14 d and then discontinuance for 1 week and intravenous drip cisplatin 75 mg/m2 on days 1-3; and control group (n = 60) undergoing a 3-week regimen including oral use of tegafur 800 mg x m(-2) x d(-1) tid for 14 d and then discontinuance for 1 week and intravenous drip of cisplatin 75 mg/m2 on days 1-3. The curative was evaluated after at least after 2 regimens.


RESULTS
There were 102 patients in the per-protocol population. The overall response rate of the FTQ group was 28. 3% (15/53), significantly higher than that of the control group (4.1%, 2/49, P = 0.004). The clinical improvement of the FTQ group was 50.9%, significantly higher than that of the control group (24.5%, P = 0.006). The main toxicities occurred in bone marrow and the digestive tract. The leucopenia and thrombocytopenia rates of the FTQ group were 47.45% and 32.22% respectively, both similar to those of the control group. There were no differences in the incidence rate of digestive canal side reaction between these 2 groups .


CONCLUSIONS
The regimen of FTQ combined with cisplatin is generally well-tolerated and has substantial antitumor activity.
Yang
Jun-lan
JL
Department of Oncology, General Hospital of People's Liberation Army, Beijing 100853, China.
Jiao
Shun-chang
SC
Dai
Guang-hai
GH
Li
Fang
F
Zhao
Hong
H
Li
Ying
Y
Xu
Jian-ming
JM
Liu
Wei
W
Zhang
Yang
Y
Niu
Run-gui
RG
Xie
Xiao-dong
XD
Song
Shu-ping
SP
Zhang
Feng-chun
FC
Lu
Hui-shan
HS
Wang
Jie
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D016037:Single-Blind Method; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
D011725:Pyridines; D005641:Tegafur; C489337:potassium oxonate; D010094:Oxonic Acid; D002945:Cisplatin; D005472:Fluorouracil; C104201:gimeracil